Andreas Hagen Røssevold

An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment

Xavier Tekpli, Tonje G. Lien, Andreas Hagen Røssevold et al. · Nature Communications · 2019 · 208 citations · Full text

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial

Andreas Hagen Røssevold, Nikolai Kragøe Andresen, Christina Bjerre et al. · Nature Medicine · 2022 · 76 citations · Full text

ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

Jon Amund Kyte, Andreas Hagen Røssevold, Ragnhild Sørum Falk et al. · Journal of Translational Medicine · 2020 · 24 citations · Full text

Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial

Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur et al. · Journal for ImmunoTherapy of Cancer · 2024 · 13 citations · Full text

Gut microbiota diversity is prognostic and associated with benefit from chemo‐immunotherapy in metastatic triple‐negative breast cancer

Andreas Ullern, Kristian Holm, Andreas Hagen Røssevold et al. · Molecular Oncology · 2024 · 13 citations · Full text